Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) have received an average rating of “Moderate Buy” from the nine analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $18.8750.

Several research analysts have recently weighed in on LXEO shares. Chardan Capital reissued a “buy” rating and set a $17.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday, January 13th. Oppenheimer reissued an “outperform” rating and set a $20.00 price target on shares of Lexeo Therapeutics in a research report on Wednesday, December 10th. HC Wainwright lowered their price target on shares of Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, January 13th. Finally, Raymond James Financial assumed coverage on shares of Lexeo Therapeutics in a research report on Wednesday, December 17th. They issued a “strong-buy” rating and a $25.00 target price on the stock.

Insider Buying and Selling

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 10,173 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $6.38, for a total value of $64,903.74. Following the transaction, the chief executive officer owned 392,483 shares of the company’s stock, valued at $2,504,041.54. This represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 5.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Avoro Capital Advisors LLC acquired a new position in Lexeo Therapeutics in the fourth quarter valued at about $32,769,000. Caitong International Asset Management Co. Ltd acquired a new position in Lexeo Therapeutics in the fourth quarter valued at about $37,000. Invesco Ltd. acquired a new position in Lexeo Therapeutics in the fourth quarter valued at about $4,598,000. Vestal Point Capital LP lifted its position in Lexeo Therapeutics by 37.7% in the fourth quarter. Vestal Point Capital LP now owns 4,475,000 shares of the company’s stock valued at $44,437,000 after buying an additional 1,225,000 shares during the last quarter. Finally, Virtus Investment Advisers LLC acquired a new position in Lexeo Therapeutics in the fourth quarter valued at about $270,000. Institutional investors and hedge funds own 60.67% of the company’s stock.

Lexeo Therapeutics Trading Up 0.9%

Shares of LXEO stock opened at $5.77 on Tuesday. The company’s 50-day moving average price is $6.55 and its 200-day moving average price is $7.98. The stock has a market cap of $427.50 million, a price-to-earnings ratio of -2.63 and a beta of 1.99. Lexeo Therapeutics has a twelve month low of $1.45 and a twelve month high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.05. As a group, equities research analysts predict that Lexeo Therapeutics will post -3.14 EPS for the current year.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.